Skip to main content
Explore URMC

URMC Logo

menu
URMC / Obstetrics & Gynecology / Gynecology Division / MenoPAUSE / December 2015 / Update on Timing of Hormone Replacement Therapy in Menopause

Update on Timing of Hormone Replacement Therapy in Menopause

Woman with hormone replacement pillsIn 1964, Dr. Robert Wilson, a gynecologist in New York City, advocated in his book Feminine Forever that all menopausal women should receive hormone replacement therapy (HRT).  The outrage of the feminist movement led the National Institutes of Health (NIH) to fund the Women’s Health Initiative (WHI) in 1991 to determine if HRT could safely protect women’s cardiovascular and bone health.  In July 2002, the trial was prematurely canceled due to findings of a statistical increase in both breast cancer and stroke.  Based on these findings and the resultant publicity, millions of women stopped their HRT, and doctors stopped prescribing HRT.  As a result of this precipitous change, the majority of menopausal women have gone without HRT for more than a decade. 

Since the WHI trial, there have been significant improvements in hormone replacement. The WHI utilized only oral conjugated estrogen (Premarin®) alone or combined with medroxyprogesterone acetate (Provera) as Prempro®. Bioidentical estrogen in the form of estradiol and pure micronized progesterone have largely replaced these hormones now, and they are more likely to be given in skin patch, cream, mist, or suppository form as a much safer vehicle to lessen liver and blood clotting effects.  The starting age for HRT is now the beginning of menopause (late 40s to early 50s) for the purpose of treating vasomotor symptoms (VMS) with the lowest estrogen dose. The WHI average starting age was 63.3 years, which generally would not be condoned now. 

Currently, duration of treatment of VMS with HRT is also undergoing reevaluation. Older teaching was that VMS for the majority of menopausal women only lasts one to three years.  However, in keeping with the experience of most practitioners and their menopausal patients, the recently published Study of Women’s Health Across the Nation (SWAN) provides a more protracted picture of VMS. In a group of 3,302 menopausal women from seven US sites who were followed from 1996 to 2013, 1,449 had VMS with a median duration of 7.4 years. Those who experienced VMS as they entered menopause had symptoms lasting longer than 11.8 years (median). Some women have VMS their whole postmenopausal life!

Does treatment of VMS make a difference?  Vasomotor symptoms are associated with poorer quality of life, negative moods, and sleep disorders.  From subjective symptoms to objective science, recent studies now link VMS to inflammatory and hematologic indicators of increased cardiovascular risks.  Women with greater than six days of hot flashes in two weeks exhibit increases in procoagulant/antifibrinolitic hematologic markers, plasminogen activator antigen (tPA-ag), and Factor VII, all of which demonstrate a link between vascular endothelial factors and autonomic neurogenic activity (VMS). Moreover, women with VMS exhibit lower bone mineral density compared to those without VMS. Lower bone density with longer life span portends increased osteoporosis with all of its sequelae in later life.  Based on these findings, it is not surprising that VMS has an impact on the economy.  Data from over 500,000 Fortune 500 health insurance claims from 1999 to 2011 show that for menopausal women experiencing untreated VMS, there were 57% more indirect productivity days lost (mostly absenteeism) compared to women treated for VMS at an incremental direct yearly cost of $339,599,459 or $770 per person per year.

Proper management of VMS has entered a new era.  Based on compounds with improved safety, newer methods of hormone delivery, and awareness of the negative impact and duration of untreated symptoms, HRT has improved the lives of many menopausal women who in the recent past were forced to endure the heat-searing effects of VMS.  We can only expect further improvements in our understanding and management of this important women’s health issue in the future. References available on request. 

By James Woods, M.D.
Dr. Woods treats patients for menopause at the Hess/Woods Gynecology Practice.

Disclaimer: The information included on this site is for general educational purposes only. It is not intended nor implied to be a substitute for or form of patient specific medical advice and cannot be used for clinical management of specific patients. Our responses to questions submitted are based solely on information provided by the submitting institution. No information has been obtained from any actual patient, and no physician-patient relationship is intended or implied by our response. This site is for general information purposes only. Practitioners seeking guidance regarding the management of any actual patient should consult with another practitioner willing and able to provide patient specific advice. Our response should also not be relied upon for legal defense, and does not imply any agreement on our part to act in a legal defense capacity.

James Woods | 12/3/2015

You may also like